The First $100 Billion Drug
By Ed McKinley
An obesity medication is reportedly poised to shatter the record for pharmaceutical sales volume
A prescription drug that combats obesity is expected to become the biggest-grossing pharmaceutical in history, ringing up five times the sales volume of its nearest competitor, an industry authority predicts.
“With modest patient penetration, we could see tirzepatide generating more than $100 billion in sales annually” for drug manufacturer Eli Lilly & Co. (LLY), says Bank of America analyst Geoffery Meacham.
That would dwarf the one-year record of $21 billion in sales that the anti-inflammatory drug Humira posted in 2021 for its maker, AbbVie (ABBV). But a tirzepatide juggernaut seems likely, partly because the medication could...
Topics
-
What Higher Tariffs Would Mean for Markets and Consumers
|Stiff proposed import duties could raise prices and might even foment trade wars -
This Bubble’s Not in Trouble: Why the 2024 Bull Run Isn’t Ready to Quit
|From AI to tax cuts—here's why this rally might be just getting started -
How Much Do Moats Matter?
By Ed McKinley
|While Buffett and Musk disagree, a company’s value can reside in its surrounding protective barrier -
Will America Issue a Central Bank Digital Currency?
By Ed McKinley
|Reactions to CBDC range from indifference to alarm -
CoreWeave: Poised to Transform AI
|CoreWeave, a Nvidia-backed pioneer of cloud services for artificial intelligence, is preparing for an IPO -
How Much Does the U.S. Really Spend on NATO and Foreign Aid?
By Ed McKinley
|The U.S. is paying less than you might think to defend Europe, and NATO members are stepping up their contributions -
$4.4 Billion Has Been Spent on This Election
By Ed McKinley
|Everybody follows presidential fundraising, but who knows where all that cash goes? -
An All-Star Panel Wades Into the Election Prediction Market Trading Pits
By Jeff Joseph
|Mark Cuban, Robert Cahaly, and others joined Luckbox’s Jeff Joseph to look several days into the future without the advantage of a crystal ball -
What’s Driving Luckbox Readers to the Voting Booth?
|Our most recent survey reveals the political thinking of our favorite group of investors -
Predicting the Unpredictable: Early Voting, Swing States and the Road to 270
|With early voting trends pointing to fresh records, the result of the 2024 presidential election will likely be once again decided by a handful of key swing states. -
Alex Karp: Meet the Self-Described Freak Leading the S&P 500’s Newest Member
By Ed McKinley
|The Palantir Technologies CEO does things his way—and it works -
What’s Driving the Price of Gold?
By Ed McKinley
|The upward pressure has resulted from economic uncertainty, stockpiling by central banks and wars raging on two continents. But will the trend remain intact? -
Why I Just Bought More Gold Bullion
|They're debasing the currency—and monetary inflation is rising with liquidity -
How Are Luckbox Readers Voting?
|You told us in our recent reader's survey. Here’s a summary of where you stand compared with recent results from national polls. -
Big Crypto’s Campaign Cash
By Ed McKinley
|Two companies have opened up their crypto wallets to lead the corporate sector in 2024 election campaign contributions -
Trump Trade 2.0: The Energy Sector Would Benefit if Trump Regains the White House
|Meanwhile, the ups and downs of Trump Media & Technology Group (DJT) stock provide a campaign barometer -
Economics Scorecard: Trump vs. Biden
|Despite differing politics and policies, the economic records of the two presidents share a common theme: resilience -
Who is Hindenburg Research?
By Ed McKinley
|The short-seller turns a profit by ferreting out corporate wrongdoing. Just ask Carl Icahn. -
From SoundHound to Lemonade: Top Small-Cap AI Stocks to Watch in 2024
|Smaller firms could be the next wave of winners in the artificial intelligence race